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Background: Skeletal muscle weakness is an important complication of chronic respiratory disease. The effect of acute exacerbations on strength in
patients with cystic ﬁbrosis is not known.
Methods: Quadriceps (QMVC) and respiratory muscle strength were measured in patients at the time of acute admission, at discharge and one
month later. Patients wore an activity monitor during admission and at one month. Convalescent values were compared to the stable clinic
population.
Results: Data were available for 13 acute admissions and 25 stable CF outpatients. Strength and other parameters including daily step count did not
differ signiﬁcantly between the stable and one month post-admission groups. At admission, QMVC was 16.7 (8.3)% lower than at convalescence,
whereas inspiratory muscle strength did not change signiﬁcantly. Reduction in QMVC did not correlate with activity levels or with markers of
systemic inﬂammation.
Conclusion: Further research is needed to identify the mechanisms responsible for the reduction in QMVC.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Skeletal muscle; Exacerbation; Physical activity1. Background
Skeletal muscle impairment is an important complication
of chronic respiratory diseases [1–3] and has long been recog-
nised as a feature of cystic fibrosis (CF) [4–10]. The largest
study to date, by Troosters et al., identified quadriceps weakness
in 56% of adult patients with CF and found it to be associated
with functional exercise capacity and time spent in physical
activity of moderate intensity [5].
In COPD, acute exacerbations are associated with a reduc-
tion in skeletal muscle strength [11,12] and frequent exacer-
bators experience a more rapid decline in fat free mass [13].⁎ Corresponding author at: Royal Brompton Hospital, Fulham Rd, London
SW3 6NP, United Kingdom. Tel.: +44 2073497775; fax: +44 2073497778.
E-mail address: n.hopkinson@ic.ac.uk (N.S. Hopkinson).
1569-1993/$ -see front matter © 2011 European Cystic Fibrosis Society. Published
doi:10.1016/j.jcf.2011.12.001The impact of acute exacerbations on skeletal muscle in CF
has not previously been studied. There is some evidence of
specific muscle abnormality in CF which may increase the
susceptibility of muscle to inflammatory stimuli via NF-κB
[14–16]. Exacerbations will increase the level of systemic
inflammation and are also likely to be associated with a re-
duction in daily physical activity with an associated risk of
muscle deconditioning.
We therefore measured physical activity and skeletal muscle
strength in patients admitted with an acute exacerbation of
CF and then repeated the measurements at discharge and one
month later once they had convalesced. Values were also com-
pared to a cohort of stable CF patients. The study also allowed
us to compare a novel ear worn activity recognition (e-AR)
device [17] against the outputs from a commercially available
device (The SenseWear Bodymedia Armband).by Elsevier B.V. All rights reserved.
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This was a prospective, observational study which was
approved by The Charing Cross Research Ethics Committee
(07/H0711/125). All participants provided written informed
consent. A convenience sample of adult CF patients admitted
over a one month period was enrolled. Patients were eligible
to participate if they had been admitted to hospital with an
acute exacerbation and excluded if they had other medical con-
ditions significantly reducing their mobility or if they were not
expected to be discharged. Measurements made within 48 h of
admission were defined as “admission”. Anthropometric data
and fat free mass, calculated using bioelectrical impedance
analysis (Bodystat Quadscan, Bodystat, Isle Of Man, UK)
were recorded. The Quadscan “illness marker” Z200/Z5 (ratio
of impedance at 200 Hz and 5 Hz) was also recorded. Test re-
sults including albumin, CRP white cell count and haemoglobin
as well as microbiology data where available were recorded.
Strength measurements were repeated at “discharge” (within
24 h of discharge from hospital) and strength and activity mea-
surements repeated one month later defined as “convalescent”.
Patients did not undergo any training program while in
the hospital. In addition, a second sample of stable patients
attending CF follow up clinics was recruited for comparison
with “stable” group (Fig. 1).
2.1. Measures of strength
Maximum isometric quadriceps strength (QMVC) was mea-
sured with subjects seated, trying to extend their dominant legDischarge – within 24 hours (n=16)
QMVC•
• PImax/PEmax
Within 48 hours of admission (n=17)
• Review medical history 
(inclusion/exclusion factors)
• FEV1/VC, Fat free mass, BMI,
• Quadriceps MVC
• CRP, Albumin, FBC
• PImax/PEmax
• SenseWear armband
• e-AR monitor
One month follow up (n=13)
• QMVC
• PImax/PEmax
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Fig. 1. Study fas hard as possible against an inextensible strap connecting
their ankle to a strain gauge (Strainstall Ltd, Cowes, UK) [18].
The signal was amplified and passed to a computer running
LabView 6 software (National Instruments, Austin, Texas).
The force generated was visible to both subject and investigator
for positive feedback and repeated efforts were made with
vigorous encouragement until there was no improvement in
performance. Efforts were sustained for at least 5 s. Subjects
rested for about 30 s between each contraction. Handgrip
strength in the dominant hand was recorded using a
Jamar Handheld dynamometer (Sammons Preston Rolyan,
Bolingbrook, IL, USA) with at least three efforts and a 30 s
gap between them.
To assess respiratory muscle strength, maximum sniff
nasal (SNiP) and static expiratory and inspiratory (PEmax and
PImax) mouth pressures were also determined [19,20].
2.2. Physical activity
Subjects wore a multi-sensor accelerometer armband
(SenseWear, BodyMedia, Pittsburgh, PA) [5] continuously
during their admission and then for a week, starting 3 weeks
after discharge. The device is a biaxial accelerometer worn
around the patient's right upper arm with the sensing device
located over the subject's triceps. In addition, galvanic skin
response, skin temperature and heat flux are recorded and pro-
prietary algorithms estimate total energy expenditure (TEE),
physical activity duration (PAD), average metabolic equiva-
lents (METs), active energy expenditure (AEE), number of
steps, duration on body and sleep duration.Stable cohort (n=25)
• Review medical history 
(inclusion/exclusion factors)
• FEV1/VC, Fat free mass,
BMI,
• QMVC
• CRP, Albumin, FBC
• PImax/PEmax
• Sensewear armband
low chart.
Table 1
Comparison of stable patients and post-exacerbation patients.
Stable group
n=25
Convalescent group
(one month
post-exacerbation)
n=13
p
Age (yrs) 33.7 (11.6) 29.8 (8.6) 0.17
Gender (number(%) female) 10 (38%) 4 (31%) 0.86
−2
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day following admission, and for “discharge” the last complete
day in hospital. The stable or convalescent values are averaged
over a median of 6 days wear.
While in hospital some of the patients also wore the e-AR ac-
tivity monitor (Sensixa Ltd). This is a novel, ultra-lightweight
(5.6×3.5×1.0 cm, 7.4 g), activity recognition sensor device
(e-AR), worn discreetly behind the ear (Fig. 2). The e-AR sensor
mainly consists of a tri-axial accelerometer, a microcontroller,
a flash memory and a wireless transceiver. Tri-axial acceler-
ometer data are stored and can be downloaded for analysis
when the device is placed on a docking station. The ADXL335
accelerometer measures acceleration with a full-scale range of
±3 g. Analogue to Digital Conversion (ADC) of this data results
in x, y, and z axes accelerometer channel outputs ranging from
0 to 4095, representing 0–3 V (or −3 g to +3 g). The e-AR
device was not worn while patients were sleeping.
An activity index (AI) is calculated from the acceleration
signals by averaging the variance per axis, calculated every mi-
nute. The e-AR sensor has been used for energy expenditure
prediction [21], activity recognition [22] and for post-
operative activity monitoring [23].
2.3. Statistical analysis
Analysis was performed using StatView 5.0 (Abacus con-
cepts, Inc., Berkeley, CA, USA). Changes in strength and phys-
ical activity over time were assessed using repeated measures
ANOVA and post hoc tests. Values were compared between
convalescent and stable patients using unpaired t tests or Chi2
tests as appropriate. Data are expressed as mean (SD) and a
p value of b0.05 was taken to be significant.
3. Results
17 patients were recruited for the acute study. One did not
comply with activity monitoring while an inpatient so data
were available for 16 individuals to cover the inpatient period.
Of these, three patients did not return for analysis (1 had gone
abroad and two declined further testing). Complete data at
one month was therefore available for 13 patients admittedFig. 2. Ear worn activity monitor (e-AR).acutely and this was compared to 25 stable patients (Table 1).
There was no difference in strength or demographics between
the stable clinic patients and those studied one month after
an acute exacerbation. In addition, daily step count and other
activity parameters did not differ between the two groups,
suggesting that they had recovered to a normal activity level.
3.1. Characteristics of combined convalescent and stable clinic
population
Combining the 38 patients in the above analysis (convales-
cent and stable) the only independent correlate of QMVC was
weight (r2 0.74 pb0.0001). QMVC was positively associated
with other measures of strength; SNIP (r2 0.16 p=0.013);
PImax (r2 0.33 p=0.0001); PEmax (r2 0.38 pb0.0001); hand-
grip (r2 0.57 pb0.0001) and body composition; FFMI (r2 0.44
pb0.0001) as well as with the Z200/Z5 impedance ratio (r
2 0.23
p=0.002). Mean step count when stable (n=38) was
7441(4154) steps. Step count did not correlate with anthropo-
metrics, with any measure of strength or with lung function or
any blood test parameter.
3.2. Effect of acute exacerbation
In the acute group white cell count 13.6 (3.2)109/L vs. 10.2
(3.3)109/L (p=0.002) and CRP 33.2 (32.3) mg/L vs. 17 (31.5)
mg/L (p=0.1) were higher at admission than in the stable group
but albumin did not differ 38.5 (4.7) g/l vs 39.1 (4.6) g/l
(p=0.8). Mean length of stay was 8.6 (3.6) days. Five patients
had documented pseudomonal, 1 cepacia and 2 staphylococcal
infections. All were on long term nebulised antibiotics. Three
were on long term prednisone and one additional patientBMI (kg m ) 22.1 (1.9) 21.0 (2.7) 0.19
FFMI (kg m−2) 17.2 (1.8) 16.9 (2.1) 0.59
Z200/Z5 impedance ratio 0.73 (0.03) 0.80 (0.02) 0.49
QMVC (kg) 38.7 (12.2) 43.8 (12.5) 0.23
SNIP (cmH2O) 88.8 (21.1)) 88.6 (21.3) 0.98
PImax (cmH2O) 83.2 (36.9) 94.5 (32.9) 0.36
PEmax (cmH2O) 96.7 (53.7) 102.6 (44.0) 0.73
Handgrip (kg) 37.0 (10.3) 36.7 (10.2) 0.93
FEV1 (l) 2.30 (0.96) 1.81 (0.42) 0.08
FEV1 %pred 64.0 (22.9) 54.0 (18.2) 0.20
FVC (l) 3.69 (1.2) 3.01 (0.48) 0.08
FVC %pred 89.8 (21.0) 75.6 (18.3) 0.02*
Steps (day−1) 7369 (4596) 7578 (3305) 0.89
BMI, body mass index; FFMI, fat free mass index; QMVC, quadriceps maxi-
mum voluntary contraction; SNIP, sniff nasal inspiratory pressure; PImax,
maximum inspiratory pressure; PEmax, maximum expiratory pressure; FEV1,
forced expiratory volume in 1 s; FVC, forced vital capacity. Step count
measured with SenseWear armband physical activity monitor. p values are for
unpaired t tests except gender (Chi2) (*pb0.05).
Fig. 3. Quadriceps strength change over time. Quadriceps maximum voluntary
contraction (QMVC) increased over time. Horizontal bars represent group
means. Repeated measures ANOVA pb0.0001, admission vs discharge
p=0.043; admission vs one month p=0.0003; discharge vs one month p=0.0009.
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admission. Spirometry improved from admission through
discharge to follow up; FEV1 1.54 (0.38)L, 1.64 (0.45)L, 1.81
(0.42) and FEV1%predicted 45.7 (15.4), 51.1 (18.8) and 54.0
(18.2) respectively (both pb0.002). Fat free mass increased
significantly from admission to convalescence; 47.9 (10.6)kg
to 48.7 (10.8)kg (p=0.007).3.3. Admission QMVC compared to convalescent values
QMVC rose from admission (Fig. 3, Table 2). Since the
values in the convalescent group were not significantly differ-
ent from those in the stable group we assumed that the conva-
lescent QMVC represented patients' “normal” strength. On
this basis we calculated the percentage reduction in QMVC atTable 2
There was a significant improvement in quadriceps strength from admission. p values
admission, discharge and one month post discharge.
n=13 Admission Discharge One month
discharge
QMVC (kg) 36.2 (8.9) 38.8 (10.6) 43.8 (12.5
PImax (cmH2O) 87.1 (22.7) 87.8 (27.7) 94.5 (32.9
PEmax (cmH2O) 83.6 (23.3) 91.5 (45.8) 102.6 (44.0
Snip (cmH2O) 89.1 (20.3) 89.4 (24.3) 88.6 (21.3
Grip (kg) 33.9 (8.0) 34.6 (8.3) 37.3 (10.2
Step count (day−1) 3684 (2805) 5038 (2619) 7507 (318
Active energy expenditure (kJ day−1) 1182 (476) 1473 (313) 1725 (529
⁎ means pb0.05the time of admission. Day 1 QMVC was 16.7 (8.3)% lower
than in the stable state. The percentage reduction did not
correlate significantly with any demographic parameter, length
of stay, CRP, albumin or white cell count, treatment with
prednisone, activity level or with the percent reduction in step
count between day 1 and the stable state. Reduction in strength
tended to be negatively associated with albumin (r2 0.18 p=0.15)
and positively with white cell count (r2 0.13 p=0.23).
3.4. Change in QMVC from admission to discharge
Median (IQR) length of stay was 9.0 (5.8) days. QMVC
rose during the course of admission by a mean 8.2 (11.7)%
(p=0.043) and this rise tended to be higher in those with the
largest percent reduction in step count (compared to convales-
cent values) (r2 0.21 p=0.11) and percent reduction in active
energy expenditure (r2 0.18 p=0.16) and lower average
METS on day 1 (r2 0.22 p=0.09). It was not associated with
length of stay or baseline CRP. Increase in QMVC during ad-
mission was positively associated with age (r2 0.30 p=0.04)
and BMI (r2 0.22 p=0.09). Only age was retained in a stepwise
model with the above variables with a larger fall in older
individuals.
3.5. Comparison of Ear worn activity monitor data
12 patients wore the e-AR device on a mean of 4.8 (2.8)
days. Correlations between minute by minute activity index
from the-AR device and minute by minute energy expenditure
(METS) from the SenseWear armband were calculated. Mean
(SD) correlation was 0.6 (0.1) and ranged from 0.42 to 0.74
(all pb0.0001) (Fig. 4).
4. Discussion
The main finding of the present study was that quadriceps
and expiratory muscle strength were significantly reduced at
the time of hospital admission in patients with an acute infec-
tive exacerbation of cystic fibrosis and that they increased
during and after the admission recovering to a normal level,
similar to a stable population one month post discharge.
In the stable state quadriceps strength was associated with
other strength measures and with fat free mass but notfor paired t tests where repeated measures ANOVA is significant. Values are at
post Repeated measures
ANOVA
Admission vs
discharge
Discharge vs
1 month
Admission vs
1 month
) b0.0001 ⁎ 0.043 ⁎ 0.0009 ⁎ 0.0003 ⁎
) 0.20 0.7 0.2 0.15
) 0.04 ⁎ 0.34 0.07 0.03 ⁎
) 0.97 0.77 0.80 0.80
) 0.02 ⁎ 0.3 0.08 0.04
7) 0.001 ⁎ 0.13 0.008 ⁎ 0.001 ⁎
) 0.002 ⁎ 0.01 ⁎ 0.06 0.001 ⁎
Fig. 4. Energy expenditure from the Sensewear armband (METs) (Panel a) e-AR
and the activity index (AI) from the e-AR monitor (b). The two measures corre-
lated with the armband R 0.74 (pb0.0001) for this individual and R 0.64(0.1)
(pb0.0001) for the whole group.
213J. Wieboldt et al. / Journal of Cystic Fibrosis 11 (2012) 209–215significantly related to measures of physical activity. In addi-
tion, the activity index of the e-AR device worn during the ad-
mission correlated well with the energy expenditure data from
the SenseWear armband.
4.1. Significance of findings
To our knowledge this is the first study to look at the effects
of acute exacerbations on muscle strength in cystic fibrosis.
The reduction in quadriceps strength associated with acute
exacerbation was of a similar order of magnitude to that seen
in acute exacerbations of COPD [11]. Exacerbations were
also associated with a reduction in daily physical activity,
with a step count at baseline roughly half of that measured in
the one month convalescent state with concomitant changes in
average and active energy expenditure.
Although some studies have found normal strength and
physical performance in children with CF [24] others have
found strength to be reduced and associated with a reduction
in exercise capacity independent of lung function [25]. The
largest study to date (n=64) by Troosters et al. found weakness
in 56% of patients with an association between the quadriceps
strength and functional exercise capacity but, as in the present
study, not with daily step count [5]. The absence of arelationship between physical activity measures and quadriceps
strength in our cohort may be a feature of sample size.
Specific muscle abnormalities have been identified in CF.
These may increase the susceptibility of muscle to inflammato-
ry stimuli via NF-κB activation of pro-inflammatory cytokines
and the E3 ubiquitin ligases (MuRF1 and atorgin-1) which
promote muscle catabolism [14–16]. Interestingly, the systemic
inflammatory response to exercise is exaggerated in patients
with CF with a greater increase in IL6 and TNFα [26]. In the
present study CRP and white cell counts were higher in the
exacerbation group, but values did not correlate significantly
with change in strength or with strength in the stable state, con-
sistent with one previous study [27]. Muscle endurance as well
as strength may be an issue; one study showed that quadriceps
fatigue occurred after exercise to a similar extent as in matched
controls though strength and exercise capacity were both less
[28] and oxidative capacity assessed during exercise using
spectroscopy has been shown to be reduced in CF [16,29].
The observation that the Z200/Z5 impedance ratio is associ-
ated with quadriceps strength is interesting as this parameter
is determined without anthropometric data. It is simple to
measure and has the potential to be examined as a biomarker
in future studies.
QMVC rose during hospital admission in contrast to
what has been observed in acute exacerbations of COPD [11].
However, the patients in the present study did not undergo
a training program but were ambulant and activity levels
increased through the admission whereas COPD inpatients
tend to be very immobile. Moreover, duration of stay was partly
determined by the need for intravenous antibiotics rather than
the point at which they had recovered sufficiently to cope at
home as is the case in COPD.
4.2. Respiratory muscle strength
Studies in CF using volitional techniques and mouth pres-
sures to assess respiratory muscle strength have found it to be
relatively well preserved, [5,30–34] except in the context of
significant nutritional depletion and hyperinflation [35–37]. In
the present study maximum expiratory but not inspiratory
pressures were reduced relative to the stable state during acute
exacerbation. Abdominal muscle recruitment occurs at lower
expiratory threshold loads in CF and in COPD where there
is also expiratory flow limitation [38] so the possibility that
abdominal muscle fatigue occurs during acute exacerbations
needs to be considered [39].
Corticosteroids have been proposed as a cause of skeletal
muscle weakness in chronic respiratory disease, though the
data to support this possibility in COPD is limited; a two
week course of prednisone had no impact on skeletal muscle
function [40] and no association has been found between
average daily dose of corticosteroids and quadriceps strength
in a cross sectional study [41]. However a correlation between
corticosteroid exposure and strength has been observed in
CF [6] and corticosteroid administration during acute exacer-
bations may therefore contribute to acute reductions in
strength. In the present study no effect of prednisone was
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conclusion from this.
The activity index derived from the e-AR monitor was sig-
nificantly correlated with data from the Sensewear armband
which supports the validity of the former measure. It should
be noted that the Sensewear armband, though widely used,
cannot be considered a gold standard for measurement of
energy expenditure. The algorithms employed have not been
validated in this population or context. We did not seek to com-
pare the AI from the e-AR sensor with the raw activity data
available from the armband as our purpose was to correlate
the e-AR against the processed outputs of the Sensewear arm-
band as the latter are used in practice.
4.3. Critique of the methods
Our findings would have been stronger if we had been able
to follow a cohort of patients prior to admission so that we
could have directly measured the fall in strength rather than
inferring it from the degree of increase in strength back to the
convalescent state. However the fact that the patient group at
one month post-exacerbation was indistinguishable from the
“stable” patients suggests that this may be a reasonable assump-
tion and this model has been used in acute exacerbations of
COPD previously [11].
Our study was not able to identify the cause of weakness
observed during acute exacerbation. Although it was not signif-
icantly correlated with severity factors (CRP, white cell count,
and length of stay) or with the degree of reduction in physical
activity compared to the stable state the trend to a greater fall
in those with the highest white cell count and lowest albumin
suggests that exacerbation related factors may be relevant and
deserve further consideration. The greater reduction in strength
in older individuals is also of interest. Larger studies are needed
to clarify this further and our pilot data should help to power
these. The severity of exacerbations was such that patients
were all able to mobilise, although physical activity levels
were reduced, so caution is needed for extrapolating these
data to patients with more severe exacerbations.
We used volitional measures of strength raising the possibil-
ity that changes seen over time were due to changes in patient
motivation. All patients received vigorous encouragement
and efforts were repeated until researchers were confident that
a maximal effort was being made. The fact that inspiratory
muscle strength measures, which are more dependent on
learning effects did not change significantly, suggests that
participants' motivation and effort were similar on all occasions
and makes a learning effect unlikely.
5. Conclusion
Our results are consistent with the hypothesis that significant
muscle weakness occurs during acute exacerbations of CF
which recovers by one month following discharge. Although
a reduction in physical activity and an increase in systemic
inflammation did occur, the present data do not identify corre-
lations that support any specific role for these factors. Furtherdata are needed to explain the mechanism for the reduction in
muscle force observed.References
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